Kornimate/medical-research-clean huggingface dataset:
a trial of a client-centered intervention aiming to improve functioning in daily life after stroke

Conditions: Stroke; Physical Disability; Multiple Disability

Summary: this is a cluster randomized controlled trial in which client-centered rehabilitation of activities of daily living (cadl) will be compared to usual rehabilitation of activities of daily living (uadl) regarding participation in activities of daily living, independence in activities of daily living and life satisfaction during the first year after stroke. in addition use of health services, caregiver burden and significant others' life satisfaction will be studied. study design, methods and power analysis are based on our previous pilot study. participating rehabilitation centers in the counties of stockholm, uppsala and gavleborg have been randomized to supply cadl or uadl. patients are included who are: \< 3 months after stroke, dependent in at least two activities of daily living, understand instructions and referred to a participating rehabilitation unit. data are collected at baseline, 3, 6 and 12 months. for sufficient power 280 participants will be included. in addition qualitative longitudinal studies will be performed in order to describe how cadl is integrated.


Eligibility criteria:
inclusion criteria: * \< 3 months after stroke * dependent in at least two activities of daily living * able to understand instructions * referred to a participating rehabilitation unit. exclusion criteria: * diagnosed dementia

Keywords: activities of daily living caregiver burden client centered life satisfaction participation patient satisfaction rehabilitation self rated impact of stroke stroke
combination neoadjuvant chemotherapy with or without apatinib for her2 negative breast cancer

Conditions: Breast Cancer

Summary: rationale: the combination of anti-angiogenic targeted therapy with neoadjuvant chemotherapy has been shown to further improve the pathologic response rate for her2-negative breast cancer patients. apatinib is a highly potent human vascular endothelial growth factor receptor 2 (vegfr2) tyrosine kinase inhibitor that has been independently developed in china, and it can exert anti-angiogenic effects by inhibiting vegfr2. it is unknown whether giving combination neoadjuvant chemotherapy together with apatinib is more effective in treating patients with nonmetastatic her2-negative breast cancer. purpose: to explore the efficacy and safety of apatinib added to weekly paclitaxel and cisplatin neoadjuvant therapy for her-2 negative breast cancer patients


Eligibility criteria:
inclusion criteria: 1. 18\~70 year-old，female 2. patients with histologically confirmed primary invasive breast adenocarcinoma,ct2-4n0-3m0 3. ecog 0-1 4. her2-negative tumor in biopsy, defined as: immunohistochemical (ihc) 0-1+ or ihc 2+ confirmed as fish negative. 5. adequate organ function exclusion criteria: 1. unwilling to use adequate contraceptive protection during the process of the study and for at least 8 weeks after the last dose of study drug. 2. pregnant or breastfeeding patients 3. metastatic or recurrent patients 4. any evidence of sense or motor nerve disorders 5. any concurrent malignancy other than breast cancer 6. uncontrolled hypertension with hypotensive drugs therapy (systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg). patients with grade i or above myocardial ischemia or myocardial infarction or arrhythmia (including qt interval ≥ 440 ms) or cardiac insufficiency 7. inability to swallow, gastrointestinal resection, chronic diarrhea and obstruction of the intestine, various factors which affect drug use and absorption 8. coagulation disorders 9. artery or venous thrombosis occurred within 6 months before the study begins 10. have received prior treatment with a vegfr tki

Keywords: apatinib neoadjuvant chemotherapy breast cancer
seprafilm in open abdomens: a study of wound and adhesion characteristics in trauma damage control patients

Conditions: Open Abdomen; Abdominal Adhesions; Trauma; Wounds and Injury

Summary: the goal of this study is to test the effects of seprafilm adhesion barrier on patients who are undergoing open abdomen damage control management for traumatic injuries when compared to no adhesion barrier use. specifically, the researchers wish to study the effects of seprafilm adhesion barrier on: * the number and intensity of adhesions, * whether there is any difference between treatment groups (seprafilm vs. no seprafilm) who go on to successful definitive abdominal closure, * rate of occurrence of secondary complications (such as abscesses) associated with short- and long-term beneficial effects of reducing adhesion formation,and * whether there is any difference between treatment groups regarding patient functional recovery.

data to be analyzed includes: age, gender, traumatic injuries, trauma alert level, procedure information, length of hospital stay, length of icu stay, interval between admission and initial operation, interval between operations, whether operation took place during the day or night, duration of operation in minutes, number of surgeons present during the operation, description of the initial operation, justification for using damage control approach, complications noted, injuries missed or delayed in diagnosis, acute physiology and chronic health evaluation ii (apache ii) calculations at various time points, simplified acute physiology score (saps ii) calculations at various time points, glasgow coma score (gcs) calculations at various time points, changes in gcs at over time, injury severity score (iss) at various time points, abbreviated injury scale (ais) at various time points, penetrating abdominal trauma index score (if applicable) at various time points, complete blood count (cbc) results at various time points, blood chemistry results at various time points, blood gas results at various time points, subject randomization information, number of operations, adhesion scores (zuhlke and yaacobi) for each operative procedure, contamination score for each operative procedure, diagnosis and description of sub-procedures for each operative procedure, wound characteristics from the start and end of all operative procedures (e.g. length and width of the fascia and skin), type of abdominal coverage or closure, discharge destination (e.g. home, short term rehabilitation facility, etc.), functional outcome measure score, glasgow outcome score (gos) at various time points, number and interval of post discharge follow-up visits, wound characteristics since discharge at several time points and complications/complaints noted since discharge at several time points.

Eligibility criteria:
inclusion criteria: * trauma patients undergoing dc/oa management for traumatic injury * age 18+ * life expectancy longer than 48 hours exclusion criteria: * prisoners * pregnant patients * younger than 18 years of age

Keywords: open abdomen damage control trauma wound healing gun shot wounds stab wounds automobile accidents wounds and injury
impact of neuro-linguistic programming on schoolchildren's performance

Conditions: Academic Skill Disorder; Child Behavior

Summary: neuro-linguistic programming (nlp) is a methodology developed in the 1970s by richard bandler and john grinder, based on the idea that language and behavior are interconnected and can be systematically modeled and changed. nlp is often used as a form of psychotherapy, coaching, or personal development, although its effectiveness has been debated in the scientific community. nlp practitioners believe that our thoughts, emotions, and behavior are influenced by our internal representations of the world, which are constructed through language and sensory experiences. changing the use of language and the perception of experiences, thoughts, emotions, and behavior can be adjusted accordingly. nlp uses various techniques to achieve this, including reframing, anchoring, and rapport-building. reframing involves changing the perception of a situation by putting it in a different context or perspective. anchoring consists in associating a particular state of mind or emotion with a specific physical or sensory stimulus, such as a touch or a smell. rapport-building involves establishing a connection and a sense of trust with another person through mirroring and matching their body language, tone of voice, and language patterns.

neuro-linguistic programming (nlp) techniques have been used in various contexts, including education. some educators and practitioners believe that nlp can help children develop their communication skills, self-confidence, and self-awareness and improve their learning outcomes. some nlp techniques adapted for children include: (1) anchoring involves linking a particular emotional or sensory state with a physical stimulus, such as a touch or a visual cue. for example, a teacher might use a specific gesture or word to help a child feel more confident before a test. (2) reframing: this technique involves helping a child see a situation or problem differently. for example, a teacher might help a child reframe a difficult math problem as a fun challenge. and (3) meta-modeling: this technique involves helping children become more aware of their language patterns and the language patterns of others, which can improve communication skills and self-awareness.

Eligibility criteria:
inclusion criteria: * schoolchildren aged between 5 and 11 years attending the same school for at least a year.
new genetic mutations in thromboembolic venous disease idiopathic. study "fit genetique".

Conditions: Thromboembolic Venous Disease

Summary: identify new genetic mutations predisposing to an increased risk of vte by locating and / or identifying genes involved in subjects at high risk for thrombotic and in whom screening for detectable hereditary thrombophilia was negative.

venous thromboembolism desease is a public health problem justifying major primary and secondary prevention policy. when vte occurs in the absence of risk factor clinically identifiable ( "idiopathic"), an inherited biological risk factor ( "inherited thrombophilia") is found in 30% of cases. however, in patients with idiopathic vte, the risk of recurrent venous thromboembolism is very high, whether detectable inherited thrombophilia was found or not. this first observation suggests that patients with idiopathic vte and no detectable thrombophilia are likely to have an underlying unknown thrombophilia that are yet to be discovered. this hypothesis is further supported by the results of the study "fit" (regional phrc 2001, promoter chu brest, investigator main: francis couturaud, ea3878 brest, france, and investigator associate: clive kearon, mcmaster university, hamilton, ontario, canada), a cross international study evaluating the risk of vte among the family members first degree of patients a first idiopathic vte episode. in this large study cross-1950 family members first degree (topics study) of 372 patients with a first episode of vte idiopathic (propositi) were included (50% included in brest and 50% inclusive in canada). the main result is that the risk of vte among family members first degree is high and similar, the proband either bearer or without a detectable hereditary thrombophilia. in other words, even in the absence of detectable hereditary thrombophilia, the risk of vte among family members first degree is high. this study has identified the subjects in that it is likely they have an inherited thrombophilia which has not yet been discovered.

Eligibility criteria:
inclusion criteria: * family members in the 1st, 2nd, 3rd and 4th degree (and their spouses if they have a descent) of patients (propositi) who: 1. / have a single episode of unprovoked venous thromboembolic disease without detectable inherited and acquired thrombophilia ; 2. / were included in the "fit" study; 3. / consenting that their family members 2nd, 3rd and 4th degree are approached to participate in the this study. * written consent of propositi and their members in the 2nd, 3rd and 4th respective degree to participate in this study. exclusion criteria: * presence of detectable thrombophilia in the propositi. * presence of hereditary thrombophilia or detectable gained at family members. * no information may be obtained on previous venous thromboembolism among family members on 1 degree * everything about the study (depending on the population and members of proband family 1st, 2nd, 3rd and 4th degree) less than 15 years. * the family member is an adopted child

Keywords: genetic thrombophilia
a molecular anatomic imaging analysis of tau in progressive supranuclear palsy

Conditions: Progressive Supranuclear Palsy

Summary: this study is designed to learn more about overall tau burden in the brain of patients with progressive supranuclear palsy (psp).


Eligibility criteria:
inclusion criteria: * must be over 35 years of age and present with gradual progression of psp-related symtoms * must have an informant or study partner that can provide independent information of functioning. * must meet criteria for possible or probable progressive supranuclear palsy. to fulfill criteria for possible psp, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. to fulfill criteria for probable psp, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset. exclusion criteria: * subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, alzheimer's disease, multiple system atrophy and parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible psp. * subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded. * women that are pregnant or post-partum and breast-feeding will be excluded. * subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: cowden disease, lynch syndrome, hypogammaglobulinemia, wiskott-aldrich syndrome, and down's syndrome. * subjects will also be excluded if mri is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy). * subjects will also be excluded if they do not have an informant, or do not consent to research.

Keywords: psp
being safe in treatment

Conditions: Risk Behavior; Sex, Unsafe; Substance Use; Risk Reduction

Summary: prior research has shown that many individuals with substance use disorders engage in hiv/sexual risk behaviors, and could strongly benefit from hiv prevention interventions that were delivered as part of their substance abuse treatment. however, discussions about sexual risk are not occurring at an appropriate frequency in treatment settings. this project will test the effects of counselor training and coaching, combined with a brief assessment and feedback tool, on counselor-patient communication about sex and on patient sexual risk behavior.


Eligibility criteria:
inclusion criteria: * admitted to substance use disorder treatment in the prior 45 days, * age 18 years or older * plan to remain in the local area for the next three months * assigned to a treatment counselor enrolled in the study. exclusion criteria: -

Keywords: hiv counselor skills training behavioral intervention personalized feedback report
development and application of rapid nucleic acid diagnostic kits for clinical specimens

Conditions: Tuberculosis; Lung Cancer

Summary: the purpose of this study is to study the development and application of rapid nucleic acid diagnostic kits for clinical specimens. subjects are divided into two groups which are health group and tuberculosis or lung cancer group in order to compare with the difference.


Eligibility criteria:
inclusion criteria: * health group: between 17 to 90 years old * tuberculosis group: people who are tuberculosis or lung cancer patients and between 17 to 90 years old exclusion criteria: * women subjects are before or after the period within two days

Keywords: tuberculosis lung cancer
efficacy and safety study of opc-1085el ophthalmic solution in subjects with glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to determine the efficacy and safety of opc-1085el ophthalmic solution in comparison with carteolol long-acting ophthalmic solution in subjects who are insufficiently responsive to carteolol long-acting ophthalmic solution.


Eligibility criteria:
inclusion criteria: * subjects with diagnosis of bilateral primary open-angle glaucoma or ocular hypertension exclusion criteria: * subjects with ocular conditions as defined by the protocol
observational study of iris tumors

Conditions: Iris Tumor

Summary: this is an observational study using oct angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. oct angiography data from healthy eyes will be compared to eyes with various types of iris tumors.


Eligibility criteria:
inclusion criteria for tumor group: * eyes with diagnosis of melanotic or amelanotic iris tumors inclusion criteria for healthy control group: * eyes without iris defects or lesions exclusion criteria (both groups): * inability to give informed consent * inability to maintain stable fixation for oct imaging * inability to commit to required study visits * eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation * mature cataracts if found to limit visual potential to worse than 20/40

Keywords: iris tumor melanoma optical coherence tomography (oct) angiography
a study of td-1211 in subjects with opioid-induced constipation (oic)

Conditions: Opioid Induced Constipation

Summary: a single-blind, pilot study to determine the tolerability and safety of td-1211 in subjects with opioid-induced constipation


Eligibility criteria:
inclusion criteria: * stable dose of opioids for at least 12 weeks before screening visit * less than or equal to 5 spontaneous bowel movements for a 2 week period and experiencing at least one other symptom of constipation * willing to stop laxatives and other bowel treatments; rescue laxative allowed exclusion criteria: * clinically significant condition or illness (other than the condition for which the pain medication was prescribed) * have participated in another clinical trial of an investigational drug 30 days prior to screening * history of cancer treatment except adequately treated localized skin cancer within 5 years of screening * history of chronic constipation prior to opioid therapy * females who are pregnant or breast feeding * have any condition that may affect drug absorption (e.g. previous gi surgery)

Keywords: opioid induced constipation oic constipation opioid side effects morphine induced constipation
a safety and efficacy study of escitalopram on acute treatment of severe depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the efficacy and safety of escitalopram treatment in participants with severe major depressive disorder (mdd \[marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation\]).

this is a single-arm (clinical study in only one group of participants), open-label (all people know the identity of the intervention), multi-center (when more than one hospital or medical school team work on a medical research study), and prospective (study following participants forward in time) study. the study consists of 2 parts: screening (that is, 5 days before study commences on day 1) and treatment (that is, week 1-8). all the eligible participants will be receiving flexible doses of escitalopram orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. efficacy will primarily be evaluated by remission rate at the end of the study. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants diagnosed with major depressive disorder (mdd) according to diagnostic and statistical manual of mental disorders-iv (dsm-iv) * scores of greater than or equal to 30 on the montgomery-asberg depression rating scale (madrs) exclusion criteria: * pregnant or lactating female participants * participants who are previously or currently diagnosed with the following mental disorders by dsm-iv: organic mental disorder, schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), schizoaffective disorder, delusional disorder, undifferentiated mental disorders and bipolar affective disorder, participants with history of drug abuse, including alcohol and drug abuse in the past 12 months * participants who have significant risk of suicide on clinical assessment (has a score of greater than or equal to 5 on item 5 of madrs) or have made a serious suicide attempt within the past 6 months and have any contraindication to escitalopram * participants who have known history of serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease currently taking other psychotropic drugs and anticonvulsant agents or continuously taking benzodiazepines or sleeping pills for over five days in the past one week * participants who have history of seizure (sudden, uncontrolled muscle spasms and loss of consciousness resulting from abnormal brain function) disorder, brain injury, any history of known neurological disease (multiple sclerosis, degenerative diseases, parkinson disease and any movement disorders) and have multiple drug adverse reactions

Keywords: major depressive disorder escitalopram lexapro